Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism-Reference-Cited by-同舟云学术

Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism

Published:2013 Issue:5 Volume:60 Page:651-663
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Shimatsu Akira¹,Teramoto Akira²³,Hizuka Naomi⁴,Kitai Kazuo⁵,Ramis Joaquim⁶,Chihara Kazuo⁷

Affiliation:

1. Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan

2. Department of Neurosurgery, Nippon Medical School, Tokyo 113-8603, Japan

3. Tokyo Rosai Hospital, Tokyo 143-0013, Japan

4. Department of Medicine II, Tokyo Women’s Medical University, Tokyo 162-8666, Japan

5. Teijin Pharma Limited, Tokyo 100-8585, Japan

6. Ipsen Innovation, Les Ulis 91940, France

7. Hyogo Prefectural Kakogawa Medical Center, Kakogawa 675-8555, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/60/5/60_EJ12-0417/_pdf

Reference20 articles.

1. 1. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355: 2558-2573.

2. 2. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25: 102-152.

3. 3. Alexander L, Applenton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 12: 71-79.

4. 4. Bates AS, Van’t Hoff W, Jones JM, Clayton RN (1993) An audit of outcome of treatment in acromegaly. Q J Med 86: 293-299.

5. 5. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2: 29-41.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance to drug treatment of acromegaly and ways to overcome it;Obesity and metabolism;2021-07-24

2. GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil;Endocrine;2021-05-26

3. Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review;Advances in Therapy;2021-01-11

4. Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan;Endocrine Journal;2021

Octreotide-Resistant Acromegaly: Challenges and Solutions

;Therapeutics and Clinical Risk Management;2020-05